Hyperlipidemia
📧 Sign up to get email alerts when something new happens for Hyperlipidemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-08-07Clinical Trial Update: Self-Assessment Method for Statin Side-effects Or Nocebo [Phase 4]
Phase 4 trial evaluating a self-assessment method to distinguish statin side effects from nocebo responses; results were posted in 2024.
-
CLINICAL_TRIALS trial_result · 2024-08-06Clinical Trial Update: The CHORAL Flow Study [Phase 4]
The CHORAL Flow Study, a Phase 4 clinical trial sponsored by Imperial College London, has been terminated. The conditions involved include c…
-
CLINICAL_TRIALS trial_result · 2024-08-01Clinical Trial Update: A Study to Assess the Safety and Pharmacokinetics of AD-104-A [Phase 1]
A Phase 1 trial evaluating the safety and pharmacokinetics of AD-104-A in hyperlipidemia has completed.
-
CLINICAL_TRIALS research · 2024-08-01Clinical Trial Update: Cholesterol Self-testing in Patients Post Acute Coronary Syndrome [NA]
A University of Leipzig-led clinical trial is evaluating cholesterol self-testing in patients after acute coronary syndrome to aid preventio…
-
FDA approval · 2024-07-30FDA Approved: FENOFIBRATE — Supplemental Application (Lupin Pharmaceuticals, Inc.)
The FDA approved Lupin Pharmaceuticals' supplemental application for Fenofibrate.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-07-30Clinical Trial Update: Unmet Social Needs Study [NA]
A completed clinical trial sponsored by the VA Office of Research and Development has posted results for an unmet social needs study involvi…
-
FDA approval · 2024-07-26FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Micro Labs Limited)
FDA approved a supplemental application for atorvastatin calcium from Micro Labs Limited, updating the approval status of this generic stati…
-
CLINICAL_TRIALS withdrawal · 2024-07-25Clinical Trial Update: Cardiovascular Risk Reduction in Epilepsy [NA]
A UCLA-sponsored clinical trial on cardiovascular risk reduction in epilepsy has been withdrawn.
-
FDA approval · 2024-07-22FDA Approved: PITAVASTATIN — Supplemental Application (Upsher-Smith Laboratories, LLC)
FDA approved Upsher-Smith's supplemental application for pitavastatin calcium (pitavastatin) under ANDA205955. This action authorizes the ma…
-
CLINICAL_TRIALS trial_result · 2024-07-17Clinical Trial Update: Effect of Evolocumab on Coronary Atherosclerosis [Phase 3]
A Phase 3 clinical trial evaluating evolocumab for its effect on coronary atherosclerosis has completed and posted results.
-
CLINICAL_TRIALS trial_result · 2024-07-16Clinical Trial Update: Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health [NA]
A completed clinical trial comparing low-carbohydrate and plant-based diets and their effects on vascular health. The study involves patient…
-
CLINICAL_TRIALS research · 2024-07-16Clinical Trial Update: Whole Grain Job's Tear, Muscle Health, Blood Glucose and Lipid Level [Phase 2]
Phase 2 trial update evaluating a whole-grain Job's tears supplement for muscle health and metabolic parameters in sarcopenia and frailty.
-
FDA approval · 2024-07-15FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Ascend Laboratories, LLC)
FDA approved a supplemental application for a generic ezetimibe and simvastatin combination product (EZETIMIBE AND SIMVASTATIN) from Ascend …
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation II [Phase 1]
A Phase 1 study of an oral protein-based tablet (Oral Formulation II) in healthy male volunteers with high cholesterol has completed, sponso…
-
CLINICAL_TRIALS trial_result · 2024-07-12Clinical Trial Update: The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients [NA]
A clinical trial update noting completion of a study evaluating the effects of omega-3 fatty acids on glucose and lipid homeostasis in obese…
-
FDA approval · 2024-07-11FDA Approved: FLUVASTATIN SODIUM — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for Fluvastatin Sodium (generic) from Lannett Company, Inc., confirming regulatory approval for this…
-
FDA approval · 2024-07-11FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application for atorvastatin calcium from Aurobindo Pharma Limited, confirming approval of a generic atorvastati…
-
FDA approval · 2024-07-11FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for atorvastatin calcium from NorthStar RxLLC, resulting in the approval of a generic atorvastatin c…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' supplemental application for ezetimibe (ANDA 210859). This is a routine supplemental approval for a gen…
-
FDA approval · 2024-07-10FDA Approved: ATORVASTATIN CALCIUM — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental ANDA for atorvastatin calcium, enabling Zydus Lifesciences Limited to market a generic atorvastatin calcium prod…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE — Supplemental Application (Marlex Pharmaceuticals, Inc.)
The FDA approved a supplemental application for ezetimibe submitted by Marlex Pharmaceuticals, Inc., granting an update to the approved gene…
-
FDA approval · 2024-07-10FDA Approved: EZETIMIBE AND SIMVASTATIN — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic Ezetimibe and Simvastatin combination from Aurobindo Pharma Limited.
-
CLINICAL_TRIALS research · 2024-07-01Clinical Trial Update: Medical Students' Evaluation of Dyslipidemia and LIPoprotein(a) Study
A ClinicalTrials.gov study led by the University of Ioannina is evaluating the prevalence of elevated lipoprotein(a) among Greek medical stu…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: Dose Escalation of SNK-396 in Participants With Elevated Low-Density Lipoprotein Cholesterol [Phase 1]
Phase 1 dose-escalation study evaluating SNK-396 in participants with elevated LDL cholesterol has completed.
-
FDA approval · 2024-06-17FDA Approved: EZETIMIBE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for ezetimibe from Ascend Laboratories, LLC.